Page 34 - Pharma Sector

Lupin's net profit jumps nearly four-fold on strong US growth, stock up

US sales cross $200 million for the first time in two years, beat analyst expectations

Divi's Laboratories Q2FY24 result: Net profit dips 29% to Rs 348 crore

Divi's Labs Q2 result: The revenue from operations, however, rose 3 per cent to Rs 1,909 crore in the period from Rs 1,855 crore last year

Sun Pharma Q2FY24 results: Net profit surges 5% to Rs 2,375.5 crore

Sun Pharma Q2 results: As compared to Rs 2,022.5 crore in the previous quarter, the net profit was up 17.4%

UK officials pressured to drop IP law demands in India trade talks

Critics say the changes would damage India's position as a leading provider of generic drugs - essentially "copycat" versions of those which fall out of patent

Mankind Pharma Q2 results: Consolidated net profit rises 21% to Rs 511 cr

Mankind Pharma on Tuesday said its consolidated net profit increased by 21 per cent to Rs 511 crore for the second quarter ended September 30, 2023, on the back of robust performance across segments. The company had reported a net profit of Rs 422 crore in the July-September period of the last fiscal. Revenue from operations rose to Rs 2,708 crore in the period under review from Rs 2,425 crore in the year-ago period, Mankind Pharma said in a regulatory filing. "The past strategic choices in various aspects of our business are showing success, and we are confident in our ability to consistently surpass the industry growth in future," Mankind Pharma Vice Chairman & Managing Director Rajeev Juneja said. Shares of Mankind Pharma on Tuesday ended 0.7 per cent lower at Rs 1,741.10 apiece on the BSE.

Ajanta Pharma Q2 results: Consolidated profit up 25% at Rs 195 crore

Ajanta Pharma Ltd on Tuesday reported a 24.71 per cent rise in consolidated net profit at Rs 195.3 crore for the second quarter ended September 30, 2023. The company had posted a consolidated net profit of Rs 156.6 crore in the same quarter last fiscal, Ajanta Pharma said in a regulatory filing. Consolidated revenue from operations was at Rs 1,028.44 crore as against Rs 938.10 crore in the year-ago period, it added. Total expenses were marginally lower at Rs 773.8 crore as compared to Rs 775.45 crore in the corresponding period a year ago, the company said. Branded generic business in India sale was at Rs 355 crore as against Rs 314 crore in the same quarter last fiscal, while the total branded generic business sales across geographies was at Rs 743 crore in Q2 as compared to Rs 711 crore in the year-ago period, up 4 per cent, it said. In the US, the generic business posted sales of Rs 237 crore as compared to Rs 185 crore in Q2 last fiscal, up 28 per cent, the company added.

US sales momentum, upward revision in margin guidance to support Cipla

The company's market share in Lanreotide (growth hormone disorder drug) improved from 18 per cent in Q1FY24 to 20 per cent now

Healthcare and pharma sector sees surge in high-value deals: Report

The Private Equity (PE) sector experienced a decline in both values and volumes compared to the previous quarter

Cipla surges 4% on beating Q2 estimates; profit jumps 43%, revenue up 15%

The positive growth was aided by strength in domestic as well as US sales. Its overall Q2 revenue was its highest ever in a quarter, Cipla said.

Dr Reddy's Laboratories Q2 results: Net profit rises 33% to Rs 1,480 crore

The company said that the Ebitda was enabled by geographic diversification and productivity improvement in operations

Cipla profit rises 45% to Rs 1,156 cr, sales up 14.4% to Rs 6,590 cr in Q2

Consolidated total revenue from the sale of products in the quarter under review stood at Rs 6,589.22 crore, up 14.41 per cent, as against Rs 5,759.28 crore in the year-ago period

Cipla Q2 net profit seen rising 25% YoY; US sales may drop QoQ to $215 mn

Cipla Q2FY24 result preview: On a sequential basis (QoQ), Cipla's net profit is seen declining 1.1 per cent, while revenue may grow 2.2 per cent

Aurobindo Pharma arm receives FDA nod for Testosterone Cypionate injection

According to research firm IQVIA, the approved product has an estimated market size of $226.8 million for the twelve months ending August 2023

Torrent lines up at least $5 billion funding to buy 33% stake in Cipla

Torrent has secured commitments from a group of overseas banks for a potential deal, the people said, asking not to be identified as the information is not public

Solara Active appoints PV Raghavendra Rao as chief financial officer

Rao is a chartered accountant from the Institute of Chartered Accountants of India (ICAI) and has about two and half decades of post-qualification experience

Haryana CM announces creation of pool of ambulances to help patients

Haryana Chief Minister Manohar Lal Khattar on Tuesday announced the setting up of a pool of government and private ambulances to provide immediate assistance to patients in need. "Patients will receive prompt assistance from the nearest available ambulance, ensuring timely and efficient medical care," he said at the monthly meeting of the District Public Relations and Grievance Redressal Committee held here. Khattar also highlighted the importance of essential medicines and added that out of the 510 medicines required, instructions have been issued to ensure the availability of 65 critical medications in hospitals at all times. Addressing a woman's complaint concerning a loan from the Friends Cooperative Building Construction Society, the chief minister ordered the immediate suspension of the deputy registrar of cooperative societies Yashpal and the dealing clerk Jasbir. Khattar announced plans to construct a new building of the Government School of Sarai Khwaja (Arya Nagar) and al

Zydus appoints Punit Patel as President & CEO for North American Operations

Punit Patel brings over 20 years of experience in both generic and branded pharmaceutical sectors

Venus Remedies gets marketing approval for 6 chemo drugs from Philippines

Pharma major Venus Remedies on Monday said it has received marketing approval from the Philippines for six key chemotherapy drugs. The approved drugs include bortezomib, cisplatin, doxorubicin, docetaxel, fluorouracil, and paclitaxel, which are crucial for cancer treatment, according to a company statement. With this, Venus Remedies has secured 525 marketing approvals for its oncology products across 76 countries, it said. This achievement marks a significant step towards achieving the company's goal of emerging as the top oncology medicine supplier from India in Southeast Asia, said Saransh Chaudhary, chief executive officer, Venus Medicine Research Centre. "While oncology drugs account for 157 of our 205 marketing authorisations in the ASEAN region, we are banking on these product registrations from the Philippines to pave the way for faster approval of these drugs in other Southeast Asian countries as well," Chaudhary added. The company will further extend its operations to oth

Israel crisis unlikely to have impact on pharma trade: Industry Experts

Pharmaceutical exports from India to Israel in FY 2020-21 amounted to $32.5 million, which represents only a minor segment of India's overall pharma exports

FDA has accepted NDA for dermatological drug Deuruxolitinib: Sun Pharma

Sun Pharmaceutical Industries Ltd said that it had submitted an 8mg twice-daily regimen of deuruxolitinib for FDA review